A phase 0/1 trigger trial of BDTX-1535 in patients with recurrent high-grade glioma (HGG) with EGFR alterations or fusions.

BDTX-1535 - Black Diamond Therap

https://meetings.asco.org/abstracts-presentations/239008/

Nader Sanai; Yoshie Umemura; Vahuni Karapetyan; Tigran Margaryan; Dylan Huttenlocher; Jocelyn Harmon; Amy Hong; Wonsuk Yoo; An-Chi Tien; Artak Tovmasyan; Shwetal Mehta

Apr 25, 2024